Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy

Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy

Background: The profile of immune-related adverse events (irAEs) due to programmed death-1 (PD-1) inhibitors-based combination therapy in advanced non-small cell lung cancer (NSCLC) and its relationship with survival have not been fully described. Objective: Designed to capture the spectrum of irAEs...

Full description

Bibliographic Details
Main Authors:	Yuzhong Chen, Yuanjian Shi, Hanlin Ding, Yipeng Feng, Te Zhang, Yingkuan Liang, Hui Wang, Xuming Song, Bing Chen, Wenjie Xia, Qixing Mao, Bo Shen, Lin Xu, Gaochao Dong, Feng Jiang
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-11-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359231210678

Similar Items

Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway
by: Te Zhang, et al.
Published: (2022-08-01)

The super-enhancer-driven lncRNA LINC00880 acts as a scaffold between CDK1 and PRDX1 to sustain the malignance of lung adenocarcinoma
by: Yipeng Feng, et al.
Published: (2023-08-01)

Tobacco exposure primes the secretion of CCL21 positively associated with tertiary lymphoid structure and response to immunotherapy
by: Hui Wang, et al.
Published: (2023-06-01)

N6‐methyladenosine‐modified circFUT8 competitively interacts with YTHDF2 and miR‐186‐5p to stabilize FUT8 mRNA to promote malignant progression in lung adenocarcinoma
by: Gaochao Dong, et al.
Published: (2023-10-01)

The Role of tRNA-Centered Translational Regulatory Mechanisms in Cancer
by: Yuanjian Shi, et al.
Published: (2023-12-01)

The molecular, immune features, and risk score construction of intraductal papillary mucinous neoplasm patients
by: Xing Huang, et al.
Published: (2022-08-01)

Hospital deaths and adverse events in Brazil
by: Pavão Ana Luiza B, et al.
Published: (2011-09-01)

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
by: Lorena Villa-Crespo, et al.
Published: (2022-02-01)

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors
by: You-Cheng Zhang, et al.
Published: (2023-01-01)

Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis
by: Jun Li, et al.
Published: (2022-11-01)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
by: Caroline Hana, et al.
Published: (2023-03-01)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
by: Walid Shalata, et al.
Published: (2023-07-01)

Mucocutaneous adverse events to immune checkpoint inhibitors
by: Fiorinda Muhaj, et al.
Published: (2023-03-01)

Ocular adverse events with immune checkpoint inhibitors
by: Tony Fang, et al.
Published: (2019-09-01)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
by: Michael R. Sayer, et al.
Published: (2023-02-01)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024-01-01)

Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis
by: Fangmin Zhao, et al.
Published: (2022-11-01)

Advances in Predictive Research of Immune Checkpoint Inhibitors-related  Adverse Events
by: Jing ZHANG, et al.
Published: (2023-10-01)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
by: Linyang Gan, et al.
Published: (2023-03-01)

SNP-Target Genes Interaction Perturbing the Cancer Risk in the Post-GWAS
by: Wenmin Yang, et al.
Published: (2022-11-01)

Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients’ Survival: Single Center Experience and Literature Review
by: Raquel Romão, et al.
Published: (2023-01-01)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
by: Vanina Vani, et al.
Published: (2020-04-01)

Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system
by: Hongxia Shi, et al.
Published: (2024-04-01)

Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article
by: Chieh-Hsun Chen, et al.
Published: (2022-04-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database
by: Lin Zhang, et al.
Published: (2022-11-01)

Individualized prevention of proton pump inhibitor related adverse events by risk stratification
by: Xia, B, et al.
Published: (2024)

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports
by: Milena M Murray, et al.
Published: (2023-08-01)

JAK-Inhibitors – A Story of Success and Adverse Events
by: Wlassits R, et al.
Published: (2024-02-01)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
by: Iñigo Les, et al.
Published: (2023-03-01)

The Rate of Adverse Events of Sodium-Glucose Cotransporter 2 Inhibitors:
by: Omar Sajdeya
Published: (2023-05-01)

Immune checkpoint inhibitors⁃related nervous system adverse events
by: WANG Ze⁃yi, et al.
Published: (2022-09-01)

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
by: Remo Poto, et al.
Published: (2022-03-01)

Thyroid-related adverse events induced by immune checkpoint inhibitors
by: Alexandra Chera, et al.
Published: (2022-09-01)

Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis
by: Tappei Takada, et al.
Published: (2024-03-01)

Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database
by: Shotaro Kobayashi, et al.
Published: (2023-04-01)

Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials
by: Haihuan Feng, et al.
Published: (2023-02-01)

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
by: Li Zeng, et al.
Published: (2023-10-01)

Ocular Adverse Events after Inactivated COVID-19 Vaccination
by: Zhihua Li, et al.
Published: (2022-06-01)

Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
by: Jingting Wang, et al.
Published: (2024-01-01)